Nabilone in Cannabis Users With PTSD

• Status: Terminated
• Trial end date: 2019-06-01
• Target enrollment: 0
• Participant gender: All

Summary

Despite the prevalence of cannabis use among the PTSD population and self-reports that it is used to help cope with PTSD symptoms, the direct effects of cannabis on PTSD symptomology are unknown. The purpose of this placebo-controlled, within-subject study is to assess the effects of smoked cannabis and orally administered nabilone, a synthetic analog of THC, the primary psychoactive component of cannabis on multiple dimensions of PTSD symptomatology in cannabis smokers with PTSD.

• Phase: Phase 1/Phase 2
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: New York State Psychiatric Institute
• Collaborator: National Institute on Drug Abuse (NIDA)
• Treatments: Dronabinol; Nabilone; Propranolol

Criteria

Inclusion Criteria:

• Current cannabis use

• PTSD symptoms

• Able to give informed consent and comply with study procedures

• Women who are normally cycling and practicing an effective form of birth control other than hormonal contraceptives

Exclusion Criteria:

• Meeting criteria for certain current psychiatric disorders

• Clinical laboratory tests outside of normal limits

• History of clinically significant cardiac or respiratory diagnoses

• Current parole or probation

• Women who are currently pregnant or breastfeeding